Senait G Ghirmai

USPTO Granted Patents = 4 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 26(Granted Patents)

Company Filing History:

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2017-2024

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11866450 - Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2024-01-09),

2. 11066417 - Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2021-07-20),

3. 9845489 - Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures (2017-12-19),

4. 9725703 - Formulations and methods for stabilizing PCR reagents (2017-08-08),

Title: Senait G Ghirmai: Pioneering Inventor from San Diego

Introduction: Senait G Ghirmai is a trailblazing inventor based in San Diego, CA, known for her innovative contributions to various fields.

Latest Patents: Senait G Ghirmai holds several patents in the areas of biotechnology, renewable energy, and medical devices, showcasing her diverse range of expertise.

Career Highlights: With a background in engineering and a passion for sustainability, Senait G Ghirmai has led groundbreaking projects that have revolutionized the way we approach environmental challenges.

Collaborations: Throughout her career, Senait G Ghirmai has collaborated with top research institutions, leading companies, and universities to bring her inventions to life and make a lasting impact on society.

Conclusion: Senait G Ghirmai's dedication to innovation and her commitment to creating a better future through her inventions make her a true inspiration in the world of technology and beyond.

This text is generated by artificial intelligence and may not be accurate.